---
title: "Formally verified POCUS risk equation predicts difficult videolaryngoscopy with high internal disc"
id: "medrxiv-2-an-interpretable-formally-verified-point-of-care-ultrasound-risk-equation-for"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-an-interpretable-formally-verified-point-of-care-ultrasound-risk-equation-for"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Formally verified POCUS risk equation predicts difficult videolaryngoscopy with high internal disc
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-an-interpretable-formally-verified-point-of-care-ultrasound-risk-equation-for
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors developed a parsimonious, fully disclosed point-of-care ultrasound (**POCUS**) risk equation to predict **difficult videolaryngoscopy** in adults undergoing elective videolaryngoscopy. - The study was a prospective, single-centre, single-operator cohort of 259 patients; difficult videolaryngoscopy (no-Easy airway) occurred in 68/259 (26.3%). - A 71-term library of nine POCUS features was screened using Sequentially Thresholded Least Squares with bootstrap stability selection (B=300), yielding a seven-term logistic equation; a pre-specified two-term bootstrap-stable model was used for robustness analysis. - Two stable interactions met the prespecified stability criterion: **skin-to-epiglottis × skin-to-hyoid-bone** distance and **tongue volume × sagittal tongue area**. - Internal validation used 5x10 repeated cross-validation plus temporal and device hold-outs; the seven-term equation achieved a cross-validated C-statistic ~0.966–0.968 and held across hold-outs (0.94–0.97). - Calibration-in-the-large matched prevalence; cross-validated slope was 0.90 with attenuation to 0.625 out-of-time; standard recalibration restored slope to 0.92 without loss of discrimination. - The two-term robustness model reproduced similar discrimination (C-statistic 0.964–0.968), events-per-parameter was 34, and shrinkage was 0.99, suggesting results are not an artifact of screening. - Decision-curve analysis showed positive net benefit over a clinical baseline across 10–50% decision thresholds. - Five behavioural properties of the equation were machine-checked and proved in Lean 4; all five Lean 4 theorems compiled without error. - The deployable equation, standardisation constants, Lean 4 theorem statements, proof project, and analysis scripts are publicly available at a Zenodo repository; the de-identified dataset is under controlled access. Screening hyperparameters are controlled under a research agreement while a patent application is pending. - Authors note limitations: single-operator cohort and operator-dependent inputs require external validation with harmonised measurement protocol and operator credentialing before wider use.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=2LJvt9drocr.kZ6EqdxhxWpBHdrHKfF0pnuCHVduhMk-1788377402.0776064-1.2.1.1-s58XcPfzBgQMRWsUagy1GruXoWvgU5kTD36O0BwmTAZQQcpMExZDtSi6Rq5sCHD9) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # An interpretable, formally verified point-of-care ultrasound risk equation for difficult videolaryngoscopy: development and internal validation [ View ORCID Profile](http://orcid.org/0009-0000-3086-9047)Ricardo Andrés Oyarzún-Silva, Pablo Hernández-Hernández, Miguel Ángel Fernández-Vaquero, Nekari De Luis-Cabezón doi: https://doi.org/10.64898/2026.08.28.26361621 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Ricardo Andrés Oyarzún-Silva 1 Hospital Universitario Puerta del Mar; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ricardo%2BAndr%C3%A9s%2BOyarz%C3%BAn-Silva%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Oyarz%C3%BAn-Silva%20RA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARicardo%2BAndr%25C3%25A9s%2BOyarz%25C3%25BAn-Silva%2B) * [ORCID record for Ricardo Andrés Oyarzún-Silva](http://orcid.org/0009-0000-3086-9047 "Open in new tab") * For correspondence: ricardooyarzun@hotmail.com Pablo Hernández-Hernández 2 Hospital Universitario Puerto Real; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Pablo%2BHern%C3%A1ndez-Hern%C3%A1ndez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hern%C3%A1ndez-Hern%C3%A1ndez%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APablo%2BHern%25C3%25A1ndez-Hern%25C3%25A1ndez%2B) Miguel Ángel Fernández-Vaquero 3 Clínica Universidad de Navarra; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Miguel%2B%C3%81ngel%2BFern%C3%A1ndez-Vaquero%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Fern%C3%A1ndez-Vaquero%20MN&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMiguel%2B%25C3%2581ngel%2BFern%25C3%25A1ndez-Vaquero%2B) Nekari De Luis-Cabezón 4 OSI Bilbao-Basurto, Osakidetza * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nekari%2BDe%2BLuis-Cabez%C3%B3n%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=De%20Luis-Cabez%C3%B3n%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANekari%2BDe%2BLuis-Cabez%25C3%25B3n%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1290146/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1290146/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1290146/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1290146/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1290146/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1290146/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background. Videolaryngoscopy still requires adjuncts or hyperangulated rescue in a clinically important minority, and bedside screening discriminates modestly. Point-of-care ultrasound (POCUS) of the anterior airway is a promising alternative, but existing prediction models are opaque or assume a pre-specified functional form. We developed and internally validated a parsimonious, fully disclosed POCUS risk equation whose form is recovered from data and whose structural properties are machine-checked by formal proof - to our knowledge the first formally verified clinical risk predictor - following TRIPOD+AI 2024. Methods. In a prospective single-centre, single-operator cohort of 259 adults undergoing elective videolaryngoscopy (no-Easy airway 68/259, 26.3%), Sequentially Thresholded Least Squares with bootstrap stability selection (B=300) screened a 71-term library of nine POCUS features and retained a seven-term logistic equation; a two-term bootstrap-stable model was pre-specified as robustness analysis. Internal validation used 5x10 repeated cross-validation plus temporal and device hold-outs, with pre-specified overfitting and optimism assessments. Five behavioural properties of the deployed equation were machine-checked in Lean 4. Results. Two interactions met the |c|/sigma_c>2 stability criterion: skin-to-epiglottis x skin-to-hyoid-bone distance and tongue volume x sagittal tongue area. The seven-term equation reached a 5x10 cross-validated C-statistic of 0.966 (optimism-corrected 0.968) and held across temporal and device hold-outs (0.94-0.97). Calibration-in-the-large matched prevalence, with cross-validated slope 0.90 attenuating to 0.625 out-of-time; standard recalibration restored 0.92 without loss of discrimination. The pre-specified two-term robustness model reproduced this performance (C-statistic 0.964-0.968; events-per-parameter 34; shrinkage 0.99), confirming the result is not an artefact of the screening stage. Net benefit over a clinical baseline was positive across 10-50% thresholds. All five Lean 4 theorems compiled without sorry. Conclusions. A sparse, formally verified POCUS equation predicts difficult videolaryngoscopy with high internally validated discrimination and quantified, modest overfitting. Because the equation was developed in a single-operator cohort and its inputs are operator-dependent, external validation requires prior harmonisation of the measurement protocol and operator credentialing. ### Competing Interest Statement A patent application covering the methods described in this manuscript is pending. R. Oyarzun-Silva and M.A. Fernandez-Vaquero are named on this pending patent application and declare this as a competing interest. The remaining authors declare that they have no competing interests. No author or institution received payments or services from a third party for any aspect of the submitted work in the past 36 months. ### Clinical Trial NCT06925009 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval was GRANTED by the Research Ethics Committee of the University of Navarra (Comite de Etica de la Investigacion, Universidad de Navarra), Pamplona, Spain, on 22 December 2022, protocol ID 2022.193 mod1. The study was registered at ClinicalTrials.gov ([NCT06925009](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT06925009&atom=%2Fmedrxiv%2Fearly%2F2026%2F09%2F02%2F2026.08.28.26361621.atom)). Written informed consent to participate was obtained from all patients prior to enrolment, and all procedures complied with the Declaration of Helsinki and Good Clinical Practice. The cohort was recruited at the Clinica Universidad de Navarra, Pamplona, Spain; this manuscript reports data from that single centre only. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The deployable equation, its standardisation constants and the five Lean 4 theorem statements are disclosed in full in the manuscript. The complete Lean 4 proof project and the analysis, validation and figure-generation scripts are publicly available at https://doi.org/10.5281/zenodo.22143665 under the PolyForm Noncommercial License 1.0.0; that repository includes a script that reproduces and verifies the deployed equation without the protected screening hyperparameters. The de-identified analysis dataset is under controlled access governed by the institutional data-access committee at Universidad de Navarra; requests are processed within 30 days for non-commercial research use. The two STLSQ screening hyperparameters remain available under a research collaboration agreement while the patent application covering the screening methodology is pending; they govern model discovery only. ## Funder Information Declared Fondos Organizacion Sanitaria Integrada (OSI) Bilbao-Basurto, Osakidetza Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.02.18.26346559v2 "In Search of Ethical Procedures for LLM-Assisted Systematic Review Production: A Proof-of-Concept Evaluation of Selected Review Components")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.26.26361331v2 "Point-of-Care Breath Volatile Organic Compound Analysis as a Tool for Lung Cancer Screening: A Pilot Feasibility Study") Posted September 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/02/2026.08.28.26361621.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/02/2026.08.28.26361621.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) An interpretable, formally verified point-of-care ultrasound risk equation for difficult videolaryngoscopy: development and internal validation Ricardo Andrés Oyarzún-Silva, Pablo Hernández-Hernández, Miguel Ángel Fernández-Vaquero, Nekari De Luis-Cabezón medRxiv 2026.08.28.26361621; doi: https://doi.org/10.64898/2026.08.28.26361621 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361621v1%26text%3DAn%2520interpretable%252C%2520formally%2520verified%2520point-of-care%2520ultrasound%2520risk%2520equation%2520for%2520difficult%2520videolaryngoscopy%253A%2520development%2520and%2520internal%2520validation "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361621v1%26t%3DAn%2520interpretable%252C%2520formally%2520verified%2520point-of-care%2520ultrasound%2520risk%2520equation%2520for%2520difficult%2520videolaryngoscopy%253A%2520development%2520and%2520internal%2520validation "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361621v1%26title%3DAn%2520interpretable%252C%2520formally%2520verified%2520point-of-care%2520ultrasound%2520risk%2520equation%2520for%2520difficult%2520videolaryngoscopy%253A%2520development%2520and%2520internal%2520validation%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361621v1%26title%3DAn%2520interpretable%252C%2520formally%2520verified%2520point-of-care%2520ultrasound%2520risk%2520equation%2520for%2520difficult%2520videolaryngoscopy%253A%2520development%2520and%2520internal%2520validation "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.28.26361621) ## Subject Area * [Anesthesia ](https://www.medrxiv.org/collection/anesthesia) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (614) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (896) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (326) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4770) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (407) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1615) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15836) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1195) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6983) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1057) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4985) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1426) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1737) * [Hematology](https://www.medrxiv.org/collection/hematology) (581) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1336) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16245) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1161) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (663) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (721) * [Neurology](https://www.medrxiv.org/collection/neurology) (7194) * [Nursing](https://www.medrxiv.org/collection/nursing) (364) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1074) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1231) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1001) * [Oncology](https://www.medrxiv.org/collection/oncology) (3574) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1037) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (393) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (446) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (466) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (704) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1774) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (759) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (583
## Related Clinical Research

- [B. animalis subsp. lactis V9 reverses CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via](https://medichelpline.com/clinical-feed/pubmed-42685222.md) (DOI: 10.1126/sciadv.aeg8202)
- [Phase II trial of TG4010 vaccine plus nivolumab in non-small cell lung cancer](https://medichelpline.com/clinical-feed/pubmed-42684015.md) (DOI: 10.1080/2162402X.2026.2695491)
- [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)
- [Deep Reinforcement Learning for Robust, Quality-of-Life–Aware NSCLC Treatment Protocols](https://medichelpline.com/clinical-feed/biorxiv-12-robust-and-quality-of-life-aware-treatment-protocols-in-nsclc-using-deep.md)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.